These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515 [TBL] [Abstract][Full Text] [Related]
5. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875 [TBL] [Abstract][Full Text] [Related]
6. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379 [TBL] [Abstract][Full Text] [Related]
7. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301 [TBL] [Abstract][Full Text] [Related]
8. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042 [TBL] [Abstract][Full Text] [Related]
9. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations]. Tasias M; Aldeguer JL Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871 [TBL] [Abstract][Full Text] [Related]
10. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A; Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798 [TBL] [Abstract][Full Text] [Related]
11. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P; PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818 [TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Santini-Oliveira M; Estrela Rde C; Veloso VG; Cattani VB; Yanavich C; Velasque L; Torres TS; Marins LM; Pilotto JH; João EC; Gonçalves JC; Grinsztejn B Antimicrob Agents Chemother; 2014 May; 58(5):2884-93. PubMed ID: 24614377 [TBL] [Abstract][Full Text] [Related]
13. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. Patterson KB; Dumond JB; Prince HA; Jenkins AJ; Scarsi KK; Wang R; Malone S; Hudgens MG; Kashuba AD J Acquir Immune Defic Syndr; 2013 May; 63(1):51-8. PubMed ID: 23221983 [TBL] [Abstract][Full Text] [Related]
14. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223 [TBL] [Abstract][Full Text] [Related]
15. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers. Calderón MM; Chairez CL; Gordon LA; Alfaro RM; Kovacs JA; Penzak SR Pharmacotherapy; 2014 Nov; 34(11):1151-8. PubMed ID: 25142999 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331 [TBL] [Abstract][Full Text] [Related]
17. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection. Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834 [TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic model of lopinavir in combination with ritonavir in human. Duangchaemkarn K; Reisfeld B; Lohitnavy M Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5699-702. PubMed ID: 25571289 [TBL] [Abstract][Full Text] [Related]
19. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905 [TBL] [Abstract][Full Text] [Related]
20. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]